儿童过敏性鼻炎粉尘螨特异性舌下免疫治疗短期疗效评估

目的 评估尘螨过敏的过敏性鼻炎患儿进行舌下免疫治疗的短期疗效。 方法 回顾性分析2019年至2020年就诊于首都儿科研究所附属儿童医院耳鼻咽喉头颈外科,应用粉尘螨舌下特异性免疫治疗满6个月的患儿,分析其治疗前后的视觉模拟量表评分(VAS)、鼻部总症状评分(TNSS)、总用药评分(TMS)、症状药物联合评分(CSMS)。 结果 共纳入50例过敏性鼻炎患儿,平均(7.7±2.7)岁。治疗前VAS、TNSS、TMS、CSMS评分分别为(5.5±1.6)分、(5.5±2.2)分、(3.0±0.1)分、(4.3±0.6)分,治疗后6个月上述评分分别为(2.5±1.4)分、(2.2±1.6)分、(0.6±1.1)分、(1.2±1.2)分,治疗后较治疗前各评分均有下降(P<0.05)。 结论 粉尘螨舌下免疫治疗对于尘螨过敏性鼻炎的患儿短期疗效较好。

Short-term effect of Dermatophagoides farinae specific sublingual immunotherapy for children with allergic rhinitis

Objective To evaluate the short-term effect of Dermatophagoides farinae specific sublingual immunotherapy for children with allergic rhinitis. Methods Children attended in the department of otorhinolaryngology head and neck surgery, Capital Institute of Pediatrics affiliated Children's Hospital and received Dermatophagoides farinae specific sublingual immunotherapy for 6 months were enrolled from 2019 to 2020. Visual analogue scale(VAS), total nasal symptoms score(TNSS), total medication score(TMS), and combined symptom and medication score(CSMS)before and after immunotherapy were collected. Results In total 50 children with allergic rhinitis were enrolled, with an average age of(7.7±2.7)years old. Before immunotherapy, VAS, TNSS, TMS and CSMS was(5.5±1.6)score,(5.5±2.2)score,(3.0±0.1)score,(4.3±0.6)score, respectively. And after immunotherapy for 6 months, VAS, TNSS, TMS and CSMS was(2.5±1.4)score,(2.2±1.6)score,(0.6±1.1)score,(1.2±1.2)score, respectively. The scores were all decreased significantly after immunotherapy(P<0.05). Conclusion Short term efficacy of Dermatophagoides farinae specific sublingual immunotherapy is good for children with allergic rhinitis.